MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ecco-jcc/jjaf092

Медицинская библиотека · Journal of Crohn's & colitis · 2025

Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy.

Linggi Bryan, Filice Melissa, Sangiorgi Bruno, Smith Michelle I, Teft Wendy, Jairath Vipul, Ma Christopher, Vande Casteele Niels

Клиническое исследование II фазыКлиническое исследование III фазыСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Ulcerative colitis (UC) therapies lead to variable remission and response rates in patients participating in clinical trials, likely due to interindividual target variability, differences in active biological pathways, feedback, and/or resistance mechanisms. Here, we stratified patients into subtypes by characterizing heterogeneity using mucosal biopsy transcriptomics data.

METHODS

Transcriptomics data from an andecaliximab phase 2/3 study in patients with UC were scored for gene signature enrichment. Eleven Reactome gene sets, moderately correlated with histological disease activity using Robarts Histopathology Index with low correlation to each other, were selected and evaluated in baseline gene expression data of ustekinumab, infliximab, and adalimumab clinical trials in patients with UC.

RESULTS

Of 11 gene sets, referred to as "Metabolism and Response to Stress" (MARS) signatures, 5 correlated with "non-disease" mucosa and 6 with "disease-related" mucosa. Clustering baseline andecaliximab samples scored with MARS revealed 3 clusters with low non-disease/high disease-related, high non-disease/low disease-related, or a mixture. Importantly, these clusters did not correlate with patient demographics, clinical characteristics, or disease activity metrics. Clustering baseline data from other clinical trials (anti-interleukin-12/23 and anti-tumor necrosis factor) in patients with UC scored with MARS showed that patients in low non-disease/high disease-related baseline score clusters less likely to achieve treatment response.

CONCLUSIONS

We identified and evaluated a novel, multi-dimensional signature gene set to characterize previously undefined heterogeneity in patients with UC and identify patients less likely to respond to therapy. This approach offers potential utility to define clinical trial populations, enrich for clinical responders, and identify difficult-to-treat populations for therapeutic development.

Для цитирования: Linggi Bryan, Filice Melissa, Sangiorgi Bruno, Smith Michelle I, Teft Wendy, Jairath Vipul, Ma Christopher, Vande Casteele Niels. Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy.. Journal of Crohn's & colitis. 2025. DOI: 10.1093/ecco-jcc/jjaf092.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.